Table 4. Patient demographics of the patient population with respective controls when subdivided according to GOLD stage at study start [mean ± (SD)].
| Variable | Total Population |
Sub-group X |
Sub-group M |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage 0n=70 | Stage 1 n=62 | Stage 2 n=95 | Stage 3/4 n=91 | Stage 0 n=51 | Stage 1 n=52 | Stage 2 n=49 | Stage 3/4 n=51 | Stage 0 n=13 | Stage 1 n=13 | Stage 2 n=14 | Stage 3/4 n=12 | |||
| Female/Male (male %) | 30/40 (57.0) | 7/55 (89.0) | 11/84 (88.0) | 3/88 (97.0) | 24/27 (53) | 5/47 (90) | 6/43 (88) | 1/50 (98) | 7/6 (46) | 0/13 (100) | 1/13 (93) | 1/11 (92) | ||
| Age at Baseline | 61.8 (8.1) | 65.2 (7.7) | 66.3 (8.3) | 65.7 (7.0) | 62.0 (7.9) | 65.7 (7.0) | 64.2 (8.9) | 66.8 (6.7)) | 62.0 (7.4) | 62.9 (3.8) | 68.0 (6.6) | 63.6 (5.4) | ||
| Number of pack years | 15.1 (20.7) | 30.1 (26.9) | 33.2 (29.4) | 42.1 (26.8) | 13.1 (20.5) | 30.9 (26.2) | 30.1 (27.8) | 40.7 (21.4) | 10.8 (16.1) | 23.9 (17.7) | 35.5 (28.6) | 32.9 (20.8) | ||
| Current smoker (%) | 20 (29.0) | 30 (48.0) | 31 (33.0) | 23 (25.0) | 12 (23.0) | 27 (52.0) | 16 (33.0) | 12 (23.0) | 3 (23.0) | 8 (62.0) | 6 (43.0) | 1 (8.0) | ||
| Former smoker (%) | 13 (18.0) | 19 (31.0) | 43 (45.0) | 62 (68.0) | 9 (18.0) | 15 (29.0) | 23 (47.0) | 37 (73.0) | 3 (23.0) | 3 (23.0) | 5 (36.0) | 9 (75.0) | ||
| Never smoker (%) | 37 (53.0) | 13 (21.0) | 21 (22.0) | 6 (7.0) | 30 (59.0) | 10 (19.0) | 10 (20.0) | 2 (4.0) | 7 (54.0) | 2 (15.0) | 3 (21.0) | 2 (17.0) | ||
| BMI (kg/m2) | 24.2 (2.9) | 23.2 (2.8) | 22.9 (3.0) | 21.6 (4.0) | 24.2 (3.0) | 23.0 (2.6) | 23.2 (2.7) | 21.1 (3.7) | 24.3 (3.6) | 22.8 (2.5) | 22.8 (3.4) | 19.9 (4.6) | ||
| FEV1 (L) | 2.35 (0.54) | 2.20 (0.48) | 1.55 (0.38) | 0.95 (0.41) | 2.31 (0.54) | 2.23 (0.45) | 1.62 (0.34) | 0.91 (0.28) | 2.29 (0.28) | 2.45 (0.41) | 1.54 (0.27) | 0.95 (0.35) | ||
| FEV1 post (L) | 2.43 (0.54) | 2.32 (0.47) | 1.72 (0.40) | 1.07 (0.44) | 2.40 (0.53) | 2.35 (0.44) | 1.80 (0.35) | 1.03 (0.31) | 2.40 (0.25) | 2.58 (0.38) | 1.76 (0.28) | 1.07 (0.40) | ||
| FEV1/FVC (%) | 79.9 (5.4) | 66.6 (6.7) | 58.3 (8.7) | 40.7 (8.9) | 80.0 (5.4) | 67.1 (6.6) | 59.0 (8.8) | 40.0 (7.4) | 81.0 (6.9) | 70.7 (8.7) | 59.4 (7.3) | 41.5 (5.4) | ||
| FRC (L) | 3.09 (0.86) | 4.03 (1.39) | 3.93 (1.19) | 4.91 (1.90) | 3.03 (0.81) | 3.95 (1.23) | 4.01 (1.13) | 4.87 (1.58) | 3.17 (0.85) | 3.97 (1.14) | 3.81 (0.82) | 5.44 (2.18) | ||
| FVC (L) | 3.06 (0.69) | 3.51 (0.70) | 2.86 (0.69) | 2.43 (0.76) | 3.01 (0.71) | 3.54 (0.67) | 3.01 (0.73) | 2.40 (0.58) | 2.97 (0.46) | 3.85 (0.50) | 2.68 (0.51) | 2.44 (0.81) | ||
| FVC post (L) | 3.05 (0.69) | 3.51 (0.72) | 2.98 (0.64) | 2.61 (0.76) | 3.01 (0.70) | 3.52 (0.69) | 3.10 (0.66) | 2.58 (0.61) | 2.99 (0.44) | 3.70 (0.63) | 2.99 (0.53) | 2.55 (0.81) | ||
| IC (L) | 2.29 (0.51) | 2.48 (0.57) | 2.15 (0.46) | 1.83 (0.59) | 2.29 (0.56) | 2.48 (0.56) | 2.22 (0.46) | 1.74 (0.48) | 2.32 (0.48) | 2.56 (0.54) | 2.23 (0.41) | 1.87 (0.55) | ||
| RV (L) | 2.50 (1.88) | 3.07 (1.41) | 3.22 (1.18) | 4.29 (1.77) | 2.56 (2.16) | 2.99 (1.25) | 3.27 (1.17) | 4.21 (1.52) | 2.45 (0.76) | 2.79 (0.86) | 3.21 (0.73) | 4.77 (2.14) | ||
| TLC (L) | 5.38 (1.11) | 6.48 (1.41) | 6.06 (1.24) | 6.72 (2.06) | 5.32 (1.14) | 6.40 (1.17) | 6.24 (1.15) | 6.60 (1.69) | 5.48 (1.11) | 6.53 (1.14) | 6.02 (0.97) | 7.31 (2.40) | ||
| DLCO (mmol/kPa x min) | 23.4 (5.0) | 20.2 (4.4) | 18.9 (5.2) | 15.4 (5.7) | 23.1 (5.0) | 19.9 (4.4) | 19.6 (4.7) | 14.4 (4.7) | 22.2 (5.1) | 22.8 (3.7) | 19.3 (4.8) | 13.9 (4.9) | ||
GOLD, global initiative for chronic obstructive lung disease; BMI, body mass index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; IC, inspiratory capacity; RV, residual volume; TLC, total lung capacity; DLCO, diffusion capacity for carbon monoxide.